BILL ANALYSIS

HR6624

NEUTRAL

Biological Intellectual Property Protection Act of 2025

HR6624 (Biological Intellectual Property Protection Act of 2025) carries an AI-assessed market impact score of 4/10 with a neutral outlook for investors. The primary sectors impacted are Healthcare and Technology. View the full bill text on Congress.gov.

4/10

Impact Score

neutral

Market Sentiment

Affected Stocks

Sectors Impacted

Key Takeaways for Investors

HR6624 restricts export of U.S. synthetic biology IP to foreign entities of concern, primarily China.

The bill has advanced out of the House Foreign Affairs Committee and awaits a full House vote.

No direct funding is authorized or appropriated by this bill; its impact is regulatory.

A companion bill (S3452) exists in the Senate, suggesting broader legislative support.

How HR6624 Affects the Market

The Biological Intellectual Property Protection Act of 2025 (HR6624) introduces new regulatory hurdles for companies in the synthetic biology sector involved in international trade, particularly with China. While no specific tickers are named, companies engaged in synthetic biology research, development, and manufacturing that have significant intellectual property or export operations will need to assess their compliance strategies. The bill's advancement indicates a continued focus on national security and intellectual property protection within the U.S. legislative agenda, potentially influencing long-term investment and operational decisions in the Healthcare and Technology sectors related to biotechnology.

Bill Details

Metric	Value
Bill Number	HR6624
Impact Score	4/10Certainty: Passed committee (+0.3 velocity (5 actions), +1.0 companion bill) · Financial Magnitude: No explicit funding identified · Strategic Weight: AI qualitative assessment: 5/10 · Market Penetration: No specific companies; 2 sector(s) identified
Market Sentiment	neutral
Event Date	April 22, 2026
Affected Sectors	Healthcare, Technology
Affected Stocks	N/A
Source	View on Congress.gov →

Summary

The Biological Intellectual Property Protection Act of 2025 (HR6624) has been ordered to be reported out of the House Foreign Affairs Committee, indicating progress towards a floor vote. This bill aims to restrict the export of U.S. intellectual property and sensitive information related to synthetic biology to foreign entities of concern, specifically citing the People's Republic of China.

Full AI Market Analysis

HR6624, the Biological Intellectual Property Protection Act of 2025, was ordered to be reported in the Nature of a Substitute (Amended) by the House Committee on Foreign Affairs on April 22, 2026, with a vote of 30-14. This action moves the bill closer to a full House vote. The bill's primary objective is to restrict the export of U.S. intellectual property and sensitive information related to synthetic biology to foreign entities of concern, particularly the People's Republic of China, citing national security threats. This bill does not authorize or appropriate specific funding amounts. Its mechanism is regulatory, imposing restrictions on exports rather than providing direct financial incentives or disbursements. Therefore, there is no direct money trail in terms of government spending. The impact will be felt through compliance costs and potential market access limitations for companies operating in the synthetic biology sector that engage with foreign entities of concern. Structural winners are not explicitly defined by this bill, as it focuses on restrictions. However, U.S. companies in the synthetic biology sector that prioritize domestic markets or allied international partnerships may face fewer operational disruptions compared to those with significant ties to entities of concern. Companies involved in synthetic biology research and development, particularly those with valuable intellectual property, will need to adapt to new export control regulations. Since the bill does not name specific companies or provide funding, no specific tickers can be identified as direct beneficiaries or losers at this stage. The bill's focus on national security and intellectual property protection aligns with broader U.S. policy trends concerning strategic technologies. As of April 24, 2026, the bill has been reported out of committee and is awaiting floor action in the House. A companion bill, S3452, has been introduced in the Senate and referred to the Committee on Banking, Housing, and Urban Affairs, indicating bipartisan and bicameral interest in the issue. The next legislative step for HR6624 is a vote by the full House of Representatives.